Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Frontiers in Cardiovascular Medicine
|
January 1, 2025
Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer
Jonathan N Le, Jordan O Gasho, Olivia Peony, et al.
Cancer Medicine
|
November 7, 2024
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System
Sean R Miller, Matthew Schipper, Lars G Fritsche, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma
Yee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
The Lancet. Oncology
|
November 17, 2024
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study
Sean Miller, Ralph Jiang, Matthew Schipper, et al.
Clinical Lung Cancer
|
March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study
Anna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Hepatology Communications
|
June 19, 2024
Development and validation of a biomarker index for HCC treatment response
Jeff Liang, Po-Yi Li, Joshua Norman, et al.
Cancer Causes & Control : CCC
|
September 4, 2025
Pre-surgery gut microbial diversity and abundance are associated with post-surgery onset of cachexia in colorectal cancer patients: the ColoCare Study
Mmadili N Ilozumba, Maria F Gomez, Tengda Lin, et al.
Cancer Cell
|
January 13, 2023
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Frontiers in Cardiovascular Medicine
|
January 1, 2025
Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer
Jonathan N Le, Jordan O Gasho, Olivia Peony, et al.
Cancer Medicine
|
November 7, 2024
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System
Sean R Miller, Matthew Schipper, Lars G Fritsche, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma
Yee Hui Yeo, Jeff Liang, Marie Lauzon, et al.
The Lancet. Oncology
|
November 17, 2024
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study
Sean Miller, Ralph Jiang, Matthew Schipper, et al.
Clinical Lung Cancer
|
March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study
Anna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Hepatology Communications
|
June 19, 2024
Development and validation of a biomarker index for HCC treatment response
Jeff Liang, Po-Yi Li, Joshua Norman, et al.
Cancer Causes & Control : CCC
|
September 4, 2025
Pre-surgery gut microbial diversity and abundance are associated with post-surgery onset of cachexia in colorectal cancer patients: the ColoCare Study
Mmadili N Ilozumba, Maria F Gomez, Tengda Lin, et al.
Cancer Cell
|
January 13, 2023
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Page
of 5